-
William Blair Upgrades Vital Therapies Ahead Of September Liver Failure Data
Monday, August 6, 2018 - 12:05pm | 381Read More...Vital Therapies, Inc. (NASDAQ: VTL) has announced the release of data for its liver failure treatment candidate. The Analysts William Blair analyst Y. Katherine Xu upgraded Vital Therapies from Market Perform to Outperform and raised the price target from $10 to $35. The Thesis Top-line...
-
William Blair Boosts OncoGenex Pharma Target To $6, Hikes Custirsen Probability To 70%
Tuesday, July 14, 2015 - 7:53am | 253Read More...In a report published Tuesday, William Blair analyst Y. Katherine Xu maintained an Outperform rating on OncoGenex Pharmaceuticals Inc (NASDAQ: OGXI), while raising the price target from $5 to $6. "OncoGenex announced that the Phase III ENSPIRIT trial of custirsen in second-line non–small-cell lung...
-
William Blair's Top BioPharma Stock Picks For Q1 2015
Friday, December 26, 2014 - 5:51pm | 946Read More...Now that 2014 is coming to an end, what stocks should investors be on the lookout for in the first quarter of the New Year? To answer this question, William Blair analyst Y. Katherine Xu named five biotechnology/biopharmaceutical stocks to watch. Medivation Medivation Inc (NASDAQ: MDVN) is...
-
UPDATE: William Blair Initiates Coverage on Infinity Pharmaceuticals on Multiple Challenges Ahead
Tuesday, September 24, 2013 - 10:55am | 225Read More...In a report published Tuesday, William Blair & Company analyst Y. Katherine Xu initiated coverage on Infinity Pharmaceuticals (NASDAQ: INFI) with a Market Perform rating and $21.00 price target. In the report, William Blair & Company noted, “Infinity's IPI-145 is a follower to ibrutinib in...
-
UPDATE: William Blair Initiates Coverage on Pharmacyclics on Good Market Position for Ibrutinib
Tuesday, September 24, 2013 - 10:55am | 192Read More...In a report published Tuesday, William Blair & Company analyst Y. Katherine Xu initiated coverage on Pharmacyclics (NASDAQ: PCYC) with an Outperform rating and $143.00 price target. In the report, William Blair & Company noted, “Pharmacyclics' ibrutinib is positioned to be the first of a...
